Literature DB >> 33255871

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials.

Marilin S Koch1, Sean E Lawler1, E Antonio Chiocca1.   

Abstract

Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resulted in the FDA-approval of the oHSV talimogene laherparepvec (T-Vec) in 2015, and several other variants are currently undergoing clinical assessment and may expand the landscape of future oncologic therapy options. This review offers a detailed overview of the latest results from clinical trials as well as an outlook on newly developed HSV-1 oncolytic variants with improved tumor selectivity, replication, and immunostimulatory capacity and related clinical studies.

Entities:  

Keywords:  HSV-1; clinical trials; immunotherapy; oncolytic virus

Year:  2020        PMID： 33255871      PMCID： PMC7760226          DOI： 10.3390/cancers12123514

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  59 in total

1.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.

Authors:  M Chase; R Y Chung; E A Chiocca
Journal:  Nat Biotechnol       Date:  1998-05       Impact factor: 54.908

3.  Morphological studies of the neural spread of herpes simplex virus to the central nervous system.

Authors:  K Kristensson
Journal:  Acta Neuropathol       Date:  1970       Impact factor: 17.088

4.  An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

Authors:  Hirokazu Kambara; Hideyuki Okano; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

Authors:  James M Markert; Shantanu N Razdan; Hui-Chien Kuo; Alan Cantor; Anette Knoll; Matthias Karrasch; L Burt Nabors; Michael Markiewicz; Bonita S Agee; Jennifer M Coleman; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; Ralph R Weichselbaum; John B Fiveash; G Yancey Gillespie
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

7.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Authors:  Neil N Senzer; Howard L Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.

Authors:  A C Shah; J N Parker; G Y Gillespie; F D Lakeman; S Meleth; J M Markert; K A Cassady
Journal:  Gene Ther       Date:  2007-04-12       Impact factor: 5.250

9.  First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.

Authors:  Keri A Streby; Mark A Currier; Melinda Triplet; Kristy Ott; Devon J Dishman; Michele R Vaughan; Mark A Ranalli; Bhuvana Setty; Micah A Skeens; Stacy Whiteside; Nicholas D Yeager; Kellie B Haworth; Kathleen Simpson; Joe Conner; Timothy P Cripe
Journal:  Mol Ther       Date:  2019-09-10       Impact factor: 11.454

10.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779
View more
  13 in total

1.  NFAT5 Regulated by STUB1, Facilitates Malignant Cell Survival and p38 MAPK Activation by Upregulating AQP5 in Chronic Lymphocytic Leukemia.

Authors:  Bei Li Chen; Yuchuan Li; Shujuan Xu; Yuwei Nie; Jiang Zhang
Journal:  Biochem Genet       Date:  2021-02-05       Impact factor: 1.890

2.  Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

Authors:  Teng He; Zhixing Hao; Mingjie Lin; Zhongwei Xin; Yongyuan Chen; Wei Ouyang; Qi Yang; Xiaoke Chen; Hui Zhou; Wanying Zhang; Pin Wu; Feng Xu
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

3.  Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus.

Authors:  Hong-My Nguyen; Naresh Sah; Melissa R M Humphrey; Samuel D Rabkin; Dipongkor Saha
Journal:  J Vis Exp       Date:  2021-05-13       Impact factor: 1.355

Review 4.  APOBECs and Herpesviruses.

Authors:  Adam Z Cheng; Sofia N Moraes; Nadine M Shaban; Elisa Fanunza; Craig J Bierle; Peter J Southern; Wade A Bresnahan; Stephen A Rice; Reuben S Harris
Journal:  Viruses       Date:  2021-02-28       Impact factor: 5.818

Review 5.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 6.  Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research.

Authors:  Upasana Sahu; Rolf F Barth; Yoshihiro Otani; Ryan McCormack; Balveen Kaur
Journal:  J Neuropathol Exp Neurol       Date:  2022-04-27       Impact factor: 3.148

Review 7.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09

8.  Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.

Authors:  Divya Ravirala; Brandon Mistretta; Preethi H Gunaratne; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

Review 9.  In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.

Authors:  Nusrat Jahan; Shanawaz M Ghouse; Robert L Martuza; Samuel D Rabkin
Journal:  Viruses       Date:  2021-08-31       Impact factor: 5.048

10.  Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.

Authors:  Irene Appolloni; Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Daniela Marubbi; Noemi Piga; Davide Ceresa; Francesca Piaggio; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Viruses       Date:  2021-08-24       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.